A refined use of mutations to guide immunotherapy decisions

Chao Cheng () and Christopher I. Amos ()

Nature, 2022, vol. 612, issue 7941, 639-641

Abstract: Assessment of a tumour’s mutational profile offers a way of predicting a person’s response to anticancer therapies called immune-checkpoint inhibitors. It seems that such approaches might fall short for people who are not of European ancestry.

Keywords: Medical research; Cancer (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-022-04448-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:612:y:2022:i:7941:d:10.1038_d41586-022-04448-z

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-022-04448-z

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().